Hepatitis A
71
2
3
51
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Published Results
21 trials with published results (30%)
Research Maturity
51 completed trials (72% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
1.4%
1 terminated out of 71 trials
98.1%
+11.6% vs benchmark
69%
49 trials in Phase 3/4
41%
21 of 51 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 51 completed trials
Clinical Trials (71)
Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People
Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents
Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV
Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents
Immunity With Acute Hepatits A
Effects of Aging on Primary and Secondary Vaccine Responses
Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old
Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children
Phase IV Study of Concomitant Administration of the sIPV and HepA
Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively
Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination.
The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines
Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs
What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years
A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis A
Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine